Background {#Sec1}
==========

Chronic exposure to air pollution has detrimental effects on human health \[[@CR1]--[@CR3]\]. However, little is known about the effects of air pollution on neurological outcomes and risk of Parkinson's disease (PD). The existence of a link between air pollution and PD risk is suggested by the observations that toxins in air pollution evoke a systemic inflammatory response and oxidative stress \[[@CR4]\], markers of which have been shown in some studies to be elevated among PD patients \[[@CR5]\]. The brain is particularly vulnerable to oxidative stress, due it's high consumption of oxygen, low level of antioxidants, high levels of polyunsaturated fatty acids and elevated iron content (particularly in the substantia nigra, a key brain area for PD) \[[@CR6]\]. Further, increased plasma levels of inflammatory markers have been associated in some studies \[[@CR7], [@CR8]\], whereas higher urate, a potent antioxidant, appears to have neuroprotective effects in experimental models \[[@CR9], [@CR10]\] and is associated with lower PD risk \[[@CR11]--[@CR13]\]. In a recent analysis, Willis et al. linked Environmental Protection Agency (EPA) data on lead, copper and mercury emissions with the Medicare dataset on the county level throughout the US, and showed increased risk of PD among participants living in urban counties with the highest reported emissions of copper and manganese \[[@CR14]\]. An adverse effect of air pollution would be consistent with evidence that in some cases PD may originate in the olfactory bulb and may thus be caused by a pathogen that enters the body through the nasal pathway \[[@CR15], [@CR16]\]. We thus examined in a large prospective study of US nurses, whether exposure to ambient PM~10~, PM~2.5~ and PM~10--2.5~ is associated with increased risk of PD.

Methods {#Sec2}
=======

We examined the effects on PD risk of exposure to particulate matter less than or equal to 10 microns (PM~10~), less than or equal to 2.5 microns (PM~2.5~), and between 2.5 and 10 microns in diameter (PM~10--2.5~) in a large prospective cohort of older women with biennially updated addresses living throughout the contiguous United States. This study was approved by the Brigham and Women's Hospital IRB.

Study population {#Sec3}
----------------

Since 1976, 121,700 female registered nurses have been participating in the Nurses' Health Study (NHS). The participants were recruited from 11 states (California, Connecticut, Florida, Maryland, Massachusetts, Michigan, New York, New Jersey, Pennsylvania, Ohio and Texas) and were between 30 and 55 years old at baseline. At baseline and every two years thereafter, participants received, at their residential address, questionnaires asking about lifestyle factors and health outcomes. A question regarding PD was first asked in 1994. The follow-up rate in the NHS has been above 90% for each follow-up cycle. Detailed description of the study cohort is provided elsewhere \[[@CR17]\]. The Institutional Review Board (IRB) at the Brigham and Women's Hospital approved this study.

Exposure assessment {#Sec4}
-------------------

Monthly exposures to ambient air pollution were estimated for each participant using spatio-temporal models, discussed in detail elsewhere \[[@CR18]--[@CR20]\]. In brief, generalized additive models of PM~10~ from 1988 through 2007 were developed \[[@CR19]\] for the continental United States (US), using monthly average PM~10~ data from EPA's Air Quality System (AQS), a nationwide network of continuous and filter-based monitors, as well as data from various other sources, including the Interagency Monitoring of Protected Visual Environments (IMPROVE) network, and several Harvard-based research studies. A geographic information system (GIS) was used to derive the following model covariates: population density, distance to nearest road, elevation, and urban land use. The estimation of PM~2.5~ was similar; however, because EPA AQS monitoring data for PM~2.5~ was not available prior to 1999, separate models were created for pre- and post-1999 PM~2.5~. To estimate PM~2.5~ prior to 1999, the model relied on measured PM~10~ pre-1999 and the PM~2.5~ to PM~10~ ratio from the spatio-temporal model post-1999, as well as estimated extinction coefficients from airport visibility data. PM~10--2.5~ was estimated by subtracting values for PM~2.5~ from those for PM~10~. All models showed little bias and a high degree of precision when evaluated with a cross-validation approach, where a sub-section of the monitors were held out to compare predicted and observed values \[[@CR19], [@CR20]\].

PD Ascertainment {#Sec5}
----------------

The method used to ascertain PD cases has been described previously \[[@CR21]\]. Briefly, since 1994, new cases of PD in the NHS have been identified through biennial questionnaires. When a participant reports PD, consent is sought from the participant to contact their treating neurologist (or internist if the neurologist is not available) and upon receipt of the consent the doctor is contacted to complete a questionnaire to confirm the diagnosis of PD and send a copy of the medical records. Of the self-reported PD cases in the NHS, we were able to contact 86% and of those, 69% provided consent to review medical records (17% did not give permission and 14% denied the diagnosis of PD). The medical records are reviewed by a movement disorder specialist (M.A.S.) blinded to the exposure status. A case is considered confirmed if the treating physician reported it as either definite or probable, or if the medical record included evidence of either a final diagnosis of PD made by a neurologist or evidence of two or more of the three cardinal signs of PD (bradykinesia, rigidity, rest tremor) in the absence of characteristics suggesting an alternate diagnosis. The main analyses were performed among confirmed cases. We performed sensitivity analyses including participants who reported PD but did not give consent to review their medical records. Of the 508 incident PD cases included in this study, 212 were definite and 296 were probable cases.

Statistical analysis {#Sec6}
--------------------

Cox proportional hazards models with age as the time scale were used to model the association between exposure to PM~10,~ PM~2.5,~ PM~10--2.5,~ and PD. Person-months of follow-up were calculated from baseline (June 30, 1990, to allow for a 2-year lag prior to the first incident PD cases reported in this study) through the end of follow-up (June 30, 2008), death or date of PD diagnosis, whichever occurred earlier. Exposure to air pollution was included in the models as a time-dependent variable that was incremented each month. We focused on the cumulative average exposure to PM~10~, PM~2.5~ and PM~10--2.5~ up to 2 years before PD diagnosis to best capture any effects of air pollution before the onset of PD. In separate models, we also considered a lag of 5 years prior to diagnosis, as well as using PM exposure in 2000, when the PM data is most complete (results not shown). Analyses were adjusted for age in months, region of the United States (northeast,/midwest/west/south), pack years smoking, smoking status (never/past/current), population density, caffeine consumption and use of ibuprofen. Regarding ibuprofen use, our questionnaire asked the following question: "On average, how many days each month do you take the following medicine (ibuprofen)", and the responses were never, 1--4 days, 5--14 days, 15--21 days, and 22 or more days. Participants taking the drug 1 or more days per month were considered ever users for the purpose of this study. We also conducted additional analyses adjusting for tract-level income and housing value, as taken from the 2000 US census \[[@CR22]\]. These were included in models as time-dependent variables. Because dietary, lifestyle and geographic factors may modify the relationship between air pollution and PD, we conducted additional analyses, stratified by smoking, caffeine intake and ibuprofen use, the main known factors related to PD risk, as well as region of the US (as the pollutant type and thus the effect on PD may differ by region). For tests of trend, the median value in each quintile was used as a continuous variable to allow for nonlinear associations. SAS version 9.1 (SAS Institute, Cary, NC, USA) was used for the statistical analyses.

Results {#Sec7}
=======

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the study population. There were 115,620 participants in the study at baseline, and 508 incident PD cases included in prospective analyses. The characteristics of the PD cases included in the study were as follows: the mean age at PD onset was 71 years, 30% were current smokers at baseline, 28% were ever users of ibuprofen (using one or more times per month), and the mean baseline caffeine among intake was 231 mg/day. The average follow-up for participants included in the analyses was 16.6 years (SD: 3.5 years). All three measures of air pollution were positively associated with population density. PM~10~ was highly correlated with both PM~2.5~ and PM~10--2.5~ (r = 0.73 and 0.82); however, PM~2.5~ and PM~10--2.5~ were not highly correlated (r = 0.26).Table 1**Age**-**standardized characteristics of the 111**,**769 study participants at baseline in 1990 with respect to categories of PM** ~**10**~PM ~10~Pollution categoryQ1\*Q2Q3Q4Median PM^a^19.022.626.031.8Age, mean (sd)58.2 (7.2)58.2 (7.2)58.1 (7.2)58.2 (7.2)Never Smoker (%)48.046.545.942.3Pack years, mean (sd)12.8 (19.3)13.1 (19.4)13.0 (19.1)13.9 (19.5)Caffeine mg/day, mean (sd)284.2(239.5)284.6(238.1)280.2(234.1)274.8(228.2)Ibuprofen ever user (%)28.728.428.726.8Census tract income^b^, USD, mean (sd)51602.9(16926)58044.3(22510.2)66772.3(26322.7)66,772.3(26322.7)(Population density)^b^, (persons/tract), mean, (sd)1436.3(2184.5)2139.3(3216.8)1922.6(3088.5)4449.4(9575.1)Region of US'Northeast Region12.218.541.861.2'Midwest region', %31.826.227.214.7'West region', %7.03.56.715.9'South region', %49.051.824.38.2\*Q (1,2,3,4) - quartiles -- categories (C1, C2, C3 and C4) for distance to road as shown in Table [3](#Tab3){ref-type="table"}.g/day: grams/day.^a^μg/m^3^ (PM).^b^tract-level variable based on the 2000 US Census.

We found no statistically significant associations between air pollution and PD risk. The relative risk (RR) comparing the top quartile to the bottom quartile of PM exposure was 0.99 (95% Confidence Intervals (CI): 0.84,1.16) for PM~10~, 1.08 (95% CI: 0.81, 1.45) for PM~2.5,~ and 0.92 (95% CI: 0.71, 1.19) for PM~10--2.5~. These results are shown in Table [2](#Tab2){ref-type="table"}.Table 2**Exposure to PM** ~**10**\ ,~ **PM** ~**2.5**\ ,~ **and PM** ~**10**--**2.5**~ **and risk of PD in the Nurses**' **Health Study**, **1990**--**2008** (**N** = **111**,**769 women at baseline**)Age adjustedMultivariate ^a^PYCasesRR95% CIRR95% CIP-trend**Quartiles of PM** ~**10**~ 3.8-21.0 μg/m^3^4844441411.00Ref1.00Ref 21.0-- 24.3 μg/m^3^4844831351.06(0.83, 1.34)1.09(0.86, 1.39) 24.3 -- 28.3 μg/m^3^4845201201.02(0.80, 1.30)1.03(0.80, 1.32) 28.3 -- 88.3 μg/m^3^4845501121.03(0.80, 1.32)1.03(0.78, 1.37)0.92**Continuous\^** **PM** ~**10**~19379965080.99(0.86, 1.12)0.99(0.84, 1.16)**Quartiles of PM** ~**2.5**~ 1.2-12.6 μg/m^3^4844291311.00Ref1.00Ref 12.6-15.0 μg/m^3^4844821311.12(0.88, 1.43)1.07(0.83, 1.38) 15.0-17.4 μg/m^3^4845131371.23(0.97, 1.57)1.14(0.88, 1.48) 17.4-73.9 μg/m^3^4845731091.17(0.90, 1.51)1.10(0.83, 1.45)0.43**Continuous\^** **PM** ~**2.5**~19379965081.17(0.90-1.51)1.08(0.81-1.45)**Quartiles of PM** ~**10**--**2.5**~ 0-7.2 μg/m^3^4844791491.00(Ref)1.00(Ref) 7.2-9.2 μg/m^3^4844961210.87(0.69, 1.11)0.91(0.71, 1.16) 9.2-12.0 μg/m^3^4844951190.87(0.68, 1.11)0.93(0.72, 1.20) 12.0-67.1 μg/m^3^4845061190.87(0.68, 1.11)0.93(0.69, 1.26)0.64**Continuous\^** **PM** ~**10**--**25**~19379965080.90(0.74-1.09)0.92(0.71-1.19)*PY*: person years; *RR*: relative risk; 95% CI: 95 percent confidence interval.^a^adjusted for age, smoking, region (northeast, midwest, west, and south), population density, caffeine intake (\<100 mg/day vs. over 100 mg/day) and ibuprofen use (ever/never user).\^per 10 μg/m^3^.

In stratified analyses, we did not observe any statistically significant interactions with smoking caffeine consumption and PM exposure (Table [3](#Tab3){ref-type="table"}). The effect of PM on PD risk did not differ significantly by region of the US.Table 3**Exposure to PM and risk of PD in the Nurses**' **Health Study**, **1990**--**2008** (**N** = **111**,**769**) **by smoking status**, **caffeine intake and ibuprofen use**PYCasesRR ^a^95% CIPYCasesRR ^a^95% CIp-intBy smoking status:Never smokersEver smokers**Quartiles of PM** ~**10**~ Q1206697731.00Ref278761681.00Ref Q2209774751.14(0.82, 1.58)275654601.03(0.72, 1.47) Q3213834630.99(0.70, 1.41)271618571.05(0.73, 1.52) Q4213834560.92(0.62, 1.36)265933561.14(0.76, 1.71)0.31**Continuous\*** **PM** ~**10**~8498352670.96(0.85, 1.09)10919652411.04(0.92, 1.18)0.42**Quartiles of PM** ~**2.5**~ Q1210817691.00Ref274637621.00Ref Q2204967691.07(0.76, 1.52)280601621.06(0.74, 1.54) Q3214387701.07(0.74, 1.53)271003671.21(0.84, 1.76) Q4219664591.06(0.72, 1.55)265724501.12(0.74, 1.69)0.58**Continuous\*** **PM** ~**2.5**~8498352671.01(0.90, 1.15)10919652411.05(0.92, 1.19)0.66**Quartiles of PM** ~**10--2.5**~ Q1212002851.00Ref273461641.00Ref Q2204860600.79(0.57, 1.11)280562611.05(0.74, 1.51) Q3210385580.77(0.54, 1.09)274925611.14(0.79, 1.65) Q4222580640.82(0.54, 1.24)263007551.05(0.67, 1.65)0.26**Continuous\^** **PM** ~**10--25**~8498352670.93(0.81, 1.05)10919652411.03(0.90, 1.18)0.41**By Caffeine intake:\<100 mg/day caffeine\> = 100 mg/day caffeineQuartiles of PM** ~**10**~ Q1196761691.00Ref287683721.00(Ref) Q2189470691.20(0.85, 1.68)295013660.99(0.70, 1.40) Q3189270731.35(0.95, 1.91)295251470.74(0.50, 1.08) Q4184296571.20(0.81, 1.78)300254550.87(0.60, 1.31)0.23**Continuous\* PM** ~**10**~7597962681.08(0.95, 1.22)11782002400.93(0.81, 1.06)0.49**Quartiles of PM** ~**2.5**~ Q119487665(Ref)289553661.00(Ref) Q2189312681.02(0.71, 1.46)295169630.77(0.53, 1.10) Q3194935741.06(0.73, 1.55)289578630.86(0.60, 1.24) Q4180673610.88(0.58, 1.32)303900480.69(0.44, 1.09)0.22**Continuous\*** **PM** ~**25**~7597962680.97(0.85, 1.10)1202992400.91(0.79, 1.04)0.38**Quartiles of PM** ~**10--2.5**~ Q1196694761.00(Ref)287785731.00(Ref) Q2185789671.05(0.75, 1.47)298707540.77(0.53, 1.10) Q3188793590.99(0.70, 1.43)295702600.86(0.60, 1,24) Q4188513661.20(0.79, 1.80)295993530.69(0.44, 1.09)0.45**Continuous\^** **PM** ~**10--25**~7597962681.04(0.92, 1.19)11782002400.91(0.79, 1.04)0.72**By use of ibuprofenNever userEver userQuartiles of PM** ~**10**~ Q13787331011.00(Ref)105711401.00(Ref) Q23759571101.22(0.93, 1.61)108526250.76(0.45, 1.26) Q3373161871.04(0.77, 1.40)111359331.03(0.63, 1.68) Q4369737951.20(0.87, 1.65)114813170.62(0.33, 1.16)0.04**Continuous**\* **PM** ~**10**~14911493751.04(0.04, 1.15)4404091150.91(0.75, 1.10)0.03**Quartiles of PM** ~**2.5**~ Q13776421011.00(Ref)106787301.00(Ref) Q23765381031.16(0.87, 1.55)107943280.81(0.47, 1.37) Q3375892981.13(0.84, 1.52)108622391.14(0.68, 1.91) Q4367516911.26(0.87, 1.55)117056180.64(0.34, 1.20)0.43**Continuous**\* **PM** ~**25**~14911493931.07(0.97, 1.18)4404091150.93(0.77, 1.12)0.38**Quartiles of PM** ~**10--2.5**~ Q13756661071.00Ref108813421.00(Ref) Q2374592900.92(0.70, 1.23)109905310.81(0.50, 1.30) Q3375149981.02(0.77, 1.35)109346210.56(0.33, 0.96) Q4372167981.01(0.76, 1.36)112339210.55(0.32, 0.97)0.01**Continuous\^** **PM** ~**10**--**25**~14975883931.01(0.92, 1.11)4404091150.80(0.67, 0.96)0.01*Abbreviations*: *PY* person years; *RR* relative risk; *95% CI* 95 percent confidence interval.^a^adjusted for age, smoking (except in smoking stratified analyses), region (northeast, midwest, west, and south), population density, caffeine intake (\<100 mg/day vs. over 100 mg/day, except in caffeine stratified analyses) and ibuprofen use (ever/never user, except in ibuprofen stratified analyses).\^per 10 μg/m^3^.

Our analyses did not differ notably with additional adjustment for tract-level income and housing value. Analyses using pollution values in 2000 as the exposure and lagging PM exposure by 5 years with respect to PD onset also did not differ materially from the primary analyses. Analyses that also included cases that did not confirm their diagnosis of PD cases were similar to the main analyses. We conducted additional sensitivity analyses among non-movers (Table [4](#Tab4){ref-type="table"}), the results of which were not significantly different from those of our main analyses.Table 4**Exposure to PM** ~**10**\ ,~ **PM** ~**2.5**\ ,~ **and PM** ~**10**--**2.5**~ **and risk of PD in the Nurses**' **Health Study among non**-**movers**, **1990**--**2008** (**N** = **80**,**544 women at baseline who did not move during the study**)Multivariate ^a^PYCasesRR95% CIP-trend**Quartiles of PM** ~**10**~ 3.8-21.0 μg/m^3^3953531231.00Ref 21.0-- 24.3 μg/m^3^3953831151.09(0.84, 1.41) 24.3 -- 28.3 μg/m^3^3954191001.00(0.76, 1.33) 28.3 -- 88.3 μg/m^3^395426900.98(0.76, 1.33)0.92**Continuous\^** **PM** ~**10**~15815804300.99(0.89, 1.09)**Quartiles of PM** ~**2.5**~ 1.2-12.6 μg/m^3^3953431101.00Ref 12.6-15.0 μg/m^3^3953831111.10(0.83, 1.45) 15.0-17.4 μg/m^3^3954091211.25(0.94, 1.65) 17.4-73.9 μg/m^3^395446881.11(0.81, 1.52)0.43**Continuous\^** **PM** ~**2.5**~1584464301.08(0.81-1.45)**Quartiles of PM** ~**10**--**2.5**~ 0-7.2 μg/m^3^3953751321.00(Ref) 7.2-9.2 μg/m^3^3953941060.93(0.71, 1.21) 9.2-12.0 μg/m^3^395397960.90(0.68, 1.20) 12.0-67.1 μg/m^3^395395960.90(0.63, 1.28)0.64**Continuous\^** **PM** ~**10**--**25**~19379964300.95(0.85-1.05)*PY*: person years; *RR*: relative risk; 95% *CI*: 95 percent confidence interval.^a^adjusted for age, smoking, region (northeast, midwest, west, and south), population density, caffeine intake (\<100 mg/day vs. over 100 mg/day) and ibuprofen use (ever/never user).\^per 10 μg/m^3^.

Discussion {#Sec8}
==========

In this study, we did not observe a statistically significant increase in PD risk associated with exposure to ambient air pollution measured as cumulative exposure to PM~2.5~, PM~10~ and PM~10--2.5~ at the residential address. We did not observe any interaction with smoking or caffeine for any of the size fractions. An interaction was observed between PM~10~ and PM~10--2.5~ and use of ibuprofen, but this this was an unexpected finding and could have occurred by chance.

PM~10~ includes all particles smaller than 10 microns in diameter; a size considered to be small enough to pass through the throat or the nose and enter the lungs, thus potentially causing harm to human health. PM~10~ includes inhalable coarse particles (PM~10--2.5~) and fine particles (PM~2.5~). Inhalable coarse particles, PM~10--2.5~ comes primarily from agricultural, mining and construction sources \[[@CR23]\]. Fine particles, PM~2.5,~ consists primarily of combustion particles from the burning of coal, wood and fuel oil and from motor vehicle emissions \[[@CR23]\]. Exposure to PM has been associated with many harmful effects on human health. The Harvard Six Cities Study \[[@CR1]\] and the American Cancer Society Study \[[@CR2]\] were the first major studies to link exposure to air pollution to all cause mortality (The RR for all cause mortality in the extended follow-up of the Harvard Six Cities Study was 1.16 (95% CI: 1.07-1.26) \[[@CR24]\]). Since then, many more studies have documented the detrimental effects of chronic exposure to air pollution on human health and survival \[[@CR24], [@CR25]\].

Prior work on air pollution and PD has been limited. Finkelstein and colleagues \[[@CR26]\], found that although markers of traffic derived air pollution did not predict PD risk, risk was increased among participants with higher Manganese (Mn) exposure (RR: 1.03; 95% CI: 1.00-1.07) for each 10 ng/m^3^ increase in Mn concentration) \[[@CR26]\]. In a recent study that used GIS to link airborne metal exposure data throughout the US to the Medicare beneficiaries database, Willis and colleagues found a higher incidence of PD in urban counties with higher industrial release of copper and manganese \[[@CR14]\]. Also, a number of studies have linked occupational manganese exposure to risk of Parkinsonian syndromes \[[@CR27], [@CR28]\] although this is thought to be distinct from PD \[[@CR29]\].

Our study's estimates of PM air pollution have an advantage over what was done in prior studies because the measures are based on a comprehensive prediction model of PM. This model allows us to estimate air pollution levels for an entire cohort of non-occupationally exposed participants at each participant's residential address. Also, our air pollution models used GIS-based spatio-temporal statistics with GIS covariates that allow us to account for small-scale variations in pollution around each woman's address and to estimate the pollution level for each address that each study participant has reported during the study period, thus giving us a more accurate measure of exposure to air pollution over time than past studies.

Animal studies suggest that PM may access the brain either through the nasal pathway or through the circulation \[[@CR15], [@CR16], [@CR23], [@CR30]\]. Fine particles in the central nervous system have been associated with increased brain inflammation in several studies \[[@CR31]--[@CR33]\]. In one study, levels of several pro-inflammatory cytokines were elevated in the brains of mice exposed to high levels of particulate matter compared to controls \[[@CR31]\]. In another study in rats, exposure to diesel exhaust was associated with an increase of a number of inflammatory factors, including whole-brain IL-6 and TNF α, among others \[[@CR34]\]. Furthermore, a study of Mexico city residents, showed higher levels of neuroinflammation of the olfactory bulb (as indicated by higher levels of COX 2 and IL1β) and higher concentrations of metals associated with PM (including manganese, nickel and chromium) among inhabitants of urban areas \[[@CR35]\]. A study using autopsies of brains from children and young adults in Mexico City, Mexico found elevation of indices on neuroinflammation and oxidative stress in the brains of participants exposed to high levels of particulate matter \[[@CR36]\]. Higher levels of inflammatory factors in the brain have been linked with increased risk of PD in several studies. PD patients had significantly higher levels of oxidized --LDL and high-sensitivity of C-reactive protein (both markers of inflammation) compared to controls in one study \[[@CR5], [@CR7]\], and elevated levels of Il-6, but not CRP in another study \[[@CR7]\].

Measurement of long-term exposure to air pollution is prone to substantial error, which under most circumstances would tend to attenuate an association with PD risk. In this study, we only had information on air pollution exposure from 1988 onwards, due to the availability of the modeled air pollution data. This period covers only adulthood exposure for our study population. It is conceivable, although this has not been determined, that the relevant etiological period may include exposure during childhood or, more generally, for a longer period of time than we were able to capture in this study. To address this issue, we conducted a sensitivity analysis restricted to women who did not move during the study (with the presumption that those women were also more likely to maintain a single residence prior to study baseline) (Table [4](#Tab4){ref-type="table"}). In analyses restricted to women who maintained the same State and County (430 PD cases) and in analyzes among women who maintained the same latitude and longitude (291 PD cases) throughout the study, our results still did not indicate a significant association between exposure to PM air pollution and risk of PD (results not shown). Furthermore, because direct measurement data on PM~2.5~ was only available post-1999, we conducted sensitivity analyses starting follow-up in 1999 and only using the 311 PD cases onset after January 1 1999. The results of these analyses did not differ significantly from our main results.

Another limitation of our study is in the exposure assessment: we did not have personal air pollution measurements in this study or indoor air pollution measures and we do not know how much time people spend indoors vs. outdoors at their address. Due to the large scale of this study, it was only possible to use indirect measures of air pollution, collected via GIS-based modeling of pollution based on values measured by monitors throughout the US. Although the models used to estimate PM in the NHS have been shown to have little bias and high precision, \[[@CR37], [@CR38]\] especially when compared with other methods of estimating air pollution \[[@CR18], [@CR19]\], some misclassification of the biologically relevant levels of individual exposure is inevitable and could have attenuated the association between air pollution and PD risk. Finally, as in most epidemiological studies of a rare disease such as PD, power and sample size restrict our ability to detect associations - in this study we had 80% power to detect relative risks of 1.45 or above, comparing the highest quartile of pollution to the lowest quartile, assuming a 2-sided test with an alpha of 0.05. We expect that associations below this threshold would have been seen as suggestive, although not statistically significant findings. Also, there is also potential for occupational exposure to air pollution with the nursing occupation, which we were unable to account for in this study. Finally, we only had information on residential address, and were not able to account for exposure to ambient air pollution during the time that our study participants spent at work.

The strengths of this study include its' large size, a long and prospective follow-up, a high response rate and the availability of PM~10~, PM~2.5~, PM~10--2.5~ estimates at each woman's residential address on a monthly basis throughout the study. The pollution data was available throughout the continental US, allowing for sufficient variability to detect a potential contrast in the analytical categories as well as representativeness of the pollution levels to which residents of the US are commonly exposed.

Conclusion {#Sec9}
==========

In summary, overall the results of this large cohort study of female nurses do not support an effect of air pollution on PD risk.
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